Zhang He, Cao Yang, Jiang Haibo, Zhou Qilin, Yang Qintai, Cheng Lei
Department of Otolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Allergy, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Clin Transl Allergy. 2025 Jan;15(1):e70020. doi: 10.1002/clt2.70020.
Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence. BODY: This review examines the current progress and future potential of digital health in allergic disease management. It highlights key advancements, including telehealth, mobile health (mHealth), artificial intelligence, clinical decision support systems (CDSS), and digital biomarkers, with a focus on their relevance to allergic disease management. The role of digital tools in improving treatment adherence, enabling remote care, and integrating environmental and patient data into personalized care models is discussed. Challenges such as data privacy, interoperability, and equitable access are addressed, alongside potential strategies to overcome these barriers.
Digital therapy will play an important role in allergic diseases, and the further development of digital therapies will effectively promote the development of clinical research, digital biomarkers, hypoallergenic environments and digital twins. More research is needed to support the progress of digital therapy for allergic diseases.
数字健康、数字医学和数字疗法将先进的计算机技术融入医疗保健领域，旨在提高效率并改善患者治疗效果。这些技术为过敏性疾病的管理提供了创新解决方案，过敏性疾病影响着全球很大一部分人口，且患病率正在上升。
本综述探讨了数字健康在过敏性疾病管理方面的当前进展和未来潜力。它突出了关键进展，包括远程医疗、移动健康（mHealth）、人工智能、临床决策支持系统（CDSS）和数字生物标志物，重点关注它们与过敏性疾病管理的相关性。讨论了数字工具在提高治疗依从性、实现远程护理以及将环境和患者数据整合到个性化护理模式中的作用。还探讨了数据隐私、互操作性和公平获取等挑战以及克服这些障碍的潜在策略。
数字疗法将在过敏性疾病中发挥重要作用，数字疗法的进一步发展将有效促进临床研究、数字生物标志物、低敏环境和数字孪生的发展。需要更多研究来支持过敏性疾病数字疗法的进展。
